MBB Public Markets I LLC Makes New Investment in Insulet Corporation $PODD

Key Points

• MBB Public Markets I LLC has acquired a new position in Insulet Corporation, purchasing 1,226 shares valued at approximately $322,000 in the first quarter.
• In the last quarter, several other institutional investors also increased their stakes in Insulet, with Gotham Asset Management raising its stake by 57.2% to own 6,827 shares.
• Insulet's recent quarterly earnings reported $1.17 earnings per share, exceeding consensus estimates, alongside a significant revenue increase of 32.9% year-over-year.

MBB Public Markets I LLC acquired a new stake in Insulet Corporation (NASDAQ:PODD - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 1,226 shares of the medical instruments supplier's stock, valued at approximately $322,000.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in Insulet by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock valued at $2,276,553,000 after purchasing an additional 178,976 shares during the period. American Century Companies Inc. boosted its holdings in Insulet by 34.8% in the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock valued at $302,686,000 after purchasing an additional 297,734 shares during the period. Groupama Asset Managment boosted its holdings in Insulet by 0.4% in the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock valued at $276,728,000 after purchasing an additional 3,759 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Insulet by 4.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier's stock valued at $177,096,000 after purchasing an additional 27,408 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in Insulet by 27,298.6% in the 1st quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier's stock valued at $1,744,100,000 after purchasing an additional 661,717 shares during the period.

Insider Buying and Selling

In other Insulet news, SVP Prem Singh sold 687 shares of the business's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company's stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.

Insulet Price Performance

PODD stock traded up $3.84 during trading on Friday, reaching $341.78. 472,873 shares of the company were exchanged, compared to its average volume of 530,837. The company has a 50-day moving average of $311.59 and a two-hundred day moving average of $291.99. The company has a market capitalization of $24.06 billion, a price-to-earnings ratio of 103.88, a P/E/G ratio of 2.81 and a beta of 1.36. Insulet Corporation has a twelve month low of $225.37 and a twelve month high of $353.50. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm's quarterly revenue was up 32.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PODD has been the subject of several analyst reports. Oppenheimer boosted their target price on shares of Insulet from $324.00 to $365.00 and gave the company an "outperform" rating in a research report on Monday, September 8th. Jefferies Financial Group restated a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Barclays boosted their target price on shares of Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research report on Thursday, August 21st. Finally, The Goldman Sachs Group initiated coverage on shares of Insulet in a research report on Friday, May 30th. They issued a "buy" rating and a $380.00 target price for the company. Sixteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $335.12.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.